These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18378939)

  • 1. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.
    Harris AH; Hill SR; Chin G; Li JJ; Walkom E
    Med Decis Making; 2008; 28(5):713-22. PubMed ID: 18378939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
    Sorenson C
    Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study.
    Harris A; Li JJ; Yong K
    Pharmacoeconomics; 2016 Apr; 34(4):393-402. PubMed ID: 26610347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: the case for remotely assisted radical prostatectomy.
    O'Malley SP; Jordan E
    Int J Technol Assess Health Care; 2007; 23(2):286-91. PubMed ID: 17493316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
    George B; Harris A; Mitchell A
    Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The cost per year of life gained: trends and internal contradictions].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2006 Nov; 150(45):2467-70. PubMed ID: 17137090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
    Scuffham PA; Whitty JA; Mitchell A; Viney R
    Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee.
    Carter D; Vogan A; Haji Ali Afzali H
    Appl Health Econ Health Policy; 2016 Aug; 14(4):401-407. PubMed ID: 26818196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
    Lexchin J; Mintzes B
    Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry.
    Owen A; Spinks J; Meehan A; Robb T; Hardy M; Kwasha D; Wlodarczyk J; Reid C
    J Med Econ; 2008; 11(2):235-43. PubMed ID: 19450082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Threshold values for cost-effectiveness ratio and public funding of medical technologies].
    Rabinovich M; Greenberg D; Shemer J
    Harefuah; 2007 Jun; 146(6):453-8, 500. PubMed ID: 17760400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.
    Harpe SE; Szeinbach SL; Caswell RJ; Corey R; McAuley JW
    J Urol; 2007 Dec; 178(6):2532-6; discussion 2536. PubMed ID: 17937937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
    Wonder M; Dunlop S
    Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.